Correction: BBS share issue completed 215 new shareholders in Sweden


Correction to BBS share issue completed 215 new shareholders in Sweden Equity Market Information release, published the 2nd of July 2019 at 9:00 CEST.
The release was published as an Equity Market Information release but should have been released as a Company Announcement. The content of the release is the same as before.

BBS – Bioactive Bone Substitutes Oyj (“BBS or “Company”), an innovator in orthobiologics, today announced the final outcome of the share issue to increase the number of shareholders in Sweden (“Offering”), for which the subscription period ended on June 30, 2019. The subscription price of the Offering has been set to SEK 28,10 per share. A total of 114 300 new shares were subscribed in the Offering and the Board of Directors has today decided to approve the subscriptions. The shareholder base in Sweden is thereby increased with approximately 215 new shareholders and BBS is provided with approximately SEK 3,2 million before transaction related costs.

The Offering in short
As announced in the press release on June 17, 2019, the Board of Directors, based on the authorization granted at the Annual General Meeting on April 5, 2019, decided on a share issue which comprised a maximum of 509,000 new shares and addressed to the public in Sweden with deviation from the shareholders' preferential rights. The purpose of the Offering, and the reasons for the deviation from the shareholders' preferential rights, is to expand the Company’s Swedish shareholder base and increase trading volumes.

The outcome
Total of 215 new shareholders subscribed for a total of 114 300 new shares in the Offering, corresponding to approximately 22 percent of the Offering. The Board of Director’s has today resolved on approval of subscriptions. The subscription price has been set at SEK 28,10 per share, which is based on the volume-weighted average price of the Company’s share on Nasdaq First North Sweden during the time period between June 17, 2019 and June 28, 2019 with a discount of 10%. BBS is thus provided with an issue payment of approximately SEK 3,2 million before share issue costs, which are expected to amount to approximately SEK 1,5 million. The strengthened position provided by this share issue enables the continued expansion through building-up the organization, in order to further commence commercialization and prepare for the start of the sale of the Company’s first ARTEBONE® product.

The Offering entails a dilution of approximately 2 percent of the number of shares and votes in the Company. The total number of shares in the Company will after the registration of new shares with the Finnish Trade Register amount to 5 204 820 shares, which is an increase of 114 300 shares.

Financial and legal advisers
Regin Corporate Finance AB acts as financial advisers in this share issue, and Smartius Oy is the legal adviser.

Delivery of the new shares subscribed for in the Offering
The new shares subscribed for in the Offering are expected to appear on the account of the subscriber around July 10, 2019.

Pekka Jalovaara, CEO
Phone: +358 505 52 92 75

This contains such information that BBS-Bioactive Bone Substitutes Oyj is required to make public under the EU’s Market Abuse Regulation. The information was provided under the auspices of the above contact person for publication on July 01, 2019 at 9:00 CEST.

Important information
This announcement is not an offer to sell or a solicitation of any offer to buy or subscribe for any securities issued by BBS-Bioactive Bone Substitutes Oyj (the "Company") in any jurisdiction where such offer or sale would be unlawful. In any EEA Member State that has implemented Directive 2003/71/EC as amended (together with any applicable implementing measures in any member State, the “Prospectus Directive”), the securities referred to in this release may only be offered in a member state (a) to any legal entity which is a qualified investor as defined in the Prospectus Directive; or (b) in any other circumstances falling within Article 3(2) of the Prospectus Directive.

The information contained herein is not for publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, South Africa or Japan. This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” (as defined in section 86(7) of the Financial Services and Markets Act 2000) and who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it.

No prospectus will be made available in connection with the matters contained in this announcement and no such prospectus is required (in accordance with the Prospectus Directive) to be published.

This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the new shares. Any investment decision to buy or subscribe for new shares in the share issue must be made solely on the basis of publicly available information.

The information in this announcement may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction or disclosure of this information in whole or in part is unauthorised. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions. This announcement does not constitute an invitation to underwrite, subscribe for or otherwise acquire or dispose of any securities in any jurisdiction. This announcement does not constitute a recommendation concerning any investor’s option with respect to the share issue. Each investor or prospective investor should conduct his, her or its own investigation, analysis and evaluation of the business and data described in this announcement and publicly available information. The price and value of securities can go down as well as up. Past performance is not a guide to future performance. Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this announcement.

About BBS – Bioactive Bone Substitutes
BBS-Bioactive Bone Substitutes Plc is a leading orthobiologic biotech company with origins in Finland. The company’s technology, Artebone®, is a next generation bone substitute that targets treatment of bone defects and healing problems in extremities such as hands and ankles, scapula and pelvis. Its superior properties stem from the natural growth factors extracted from reindeer bone combined with scaffold-providing TCP (tricalciumphosphate) granules and has the potential of transforming orthopedic surgery. The first product, Artebone® ready-to-use paste, is complete and the application process for the CE-marking enabling commercialization is in progress. BBS’ Certified Adviser at Nasdaq First North Sweden and Finland is Stockholm Certified Advisers AB, +46 70 5516 729, More information: